NCT06922279View on ClinicalTrials.gov

First Line gastroeSOphageal metastatiC canceR primAry and disTant (if Oligometastatic) lEsions-directed Radiotherapy, a Multicentric, Phase III, Randomized Controlled Trial

NAActive, not recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

October 30, 2029

Study Completion Date

November 30, 2029

Conditions
Gastroesophageal Cancer (GC)
Interventions
RADIATION

Radiation Therapy + standard sistemic therapy (chemoteraphy)

Standard systemic therapy (chemotherapy treatment with carboplatin-taxol or with drugs that the oncologist considers most useful) + combination of RT on the primary gastroesophageal Gross Tumor Volume (GTV) + SBRT on each of the distal lesions for oligometastatic or limited metastatic spread patients (to be delivered prior to initiation of systemic therapy).

DRUG

Standard systemic therapy (chemotherapy)

The patients will go to standard therapy (chemotherapy treatment with carboplatin-taxol or with drugs that the oncologist that the oncologist considers most useful.) without RT/SBRT combination

Trial Locations (1)

00168

Policlinico Universitario Agostino Gemelli IRCSS, Rome

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT06922279 - First Line gastroeSOphageal metastatiC canceR primAry and disTant (if Oligometastatic) lEsions-directed Radiotherapy, a Multicentric, Phase III, Randomized Controlled Trial | Biotech Hunter | Biotech Hunter